Can an early phase clinical pharmacology study replace a thorough QT study? Experience with a novel H3-receptor antagonist/inverse agonist
Crossref DOI link: https://doi.org/10.1007/s00228-016-2023-3
Published Online: 2016-02-16
Published Print: 2016-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Shah, Rashmi R.
Maison-Blanche, Pierre
Robert, Philippe
Denis, Emmanuel
Duvauchelle, Thierry
Funding for this research was provided by:
Bioprojet Pharma, Paris (France)
Text and Data Mining valid from 2016-02-16